Cytomedix Inc. drew attention to the regenerative medicine space Wednesday afternoon with the acquisition of privately held Aldagen Inc., which is developing autologous cell-based therapeutics for tissue repair and regeneration. Read More
It sounds like a too-good-to-be-true idea that could come from New Age advocates of alternative cancer "treatments." But it is backed by top-notch science: A team of researchers discovered that short periods of fasting not only markedly boosted the effectiveness of chemotherapy on cancer cells, but simultaneously reduced its toxicity to normal cells. Read More
ChemoCentryx Inc. raised $45 million in its initial public offering (IPO), following Cempra Inc. and Verastem Inc. out an IPO window that, over the last few years, has proved selective at best. Read More
To create product candidate AVP-923, Avanir Pharmaceuticals Inc. bundled cough medicine dextromethorphan with antiarrhythmic agent quinidine. Now the duo of medicine cabinet staples has prevailed against an unrelated third indication: diabetic peripheral neuropathy. Read More
• GlobeImmune Inc., of Louisville, Colo., said it started a Phase I trial of GI-6301 , a Targmogen candidate, in patients with metastatic cancers containing brachyury protein, which is overexpressed in tumor types such as breast, colon, lung and prostate cancers. Read More
• Illumina Inc., of San Diego, said its board urged shareholders to reject the unsolicited $5.7 billion bid from Basel, Switzerland-based Roche AG. The big pharma has said it plans to nominate a slate of candidates for election to Illumina's board. Read More
